/PRNewswire/ MEDSIR announced today the positive results of the PHERGain trial. This study is the first to use an adaptive design that tailors treatment in.
Washington, June 1 (EFE) – Chicago transforms into the hub of oncology research from Friday until Tuesday, as the American Society of Clinical Oncology (ASCO) is set to host its annual conference in the city once again, with a spotlight on less invasive treatments and enhancing the doctor-patient relationship. According to the organizers, this collaboration …
Immune B-cells May Aid in Predicting HER2+ Breast Cancer Treatment miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
Six Months of Trastuzumab Effective in HER2+ Breast Cancer medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.